

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sanai Health Industry Group Company Limited**

**三愛健康產業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1889)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE PROPOSED ISSUE OF CONVERTIBLE NOTES UNDER GENERAL MANDATE**

Reference is made to the announcement of the Company date 13 January 2022 in relation to the proposed issue of the Convertible Notes under the General Mandate (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

The Board would like to provide additional information regarding the intended use of proceeds from the issue of the Convertible Notes.

The net proceeds from the issue of the Convertible Notes are approximately HK\$71.7 million. The Company intends to use the net proceeds from the issue of the Convertible Notes primarily for the general working capital of the Company’s pharmaceutical products business. In particular,

- approximately 45% of the net proceeds will be used for the purchase of production plant, equipment and facilities and the purchase of raw materials for pharmaceutical products;
- approximately 30% of the net proceeds will be used for the enrichment of the pharmaceutical product base, including the development of new medicines and/or the acquisition of the drug licenses; and
- approximately 25% of the net proceeds will be used for the addition of sales points and the staff costs of additional sales staffs.

By order of the Board  
**Sanai Health Industry Group Company Limited**  
**CHEN Chengqing**  
*Chairman*

Hong Kong, 26 January 2022

*As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.*